BACKGROUND. Hydroxyurea increases the production of fetal hemoglobin (hemoglobin F) in patients with sickle cell anemia and therefore has the potential for alleviating both the hemolytic and vaso-occlusive manifestations of the disease. There is preliminary evidence that recombinant human erythropoietin may also increase hemoglobin F production. METHODS and RESULTS. We treated five patients with sickle cell disease with escalating doses of intravenous erythropoietin for eight weeks. Three of these patients were subsequently treated with daily doses of oral hydroxyurea. After the optimal dose was determined, erythropoietin was then given along with hydroxyurea for four weeks. Treatment with erythropoietin, either alone or in combination with hydroxyurea, had no significant effect on the percentage of hemoglobin F-containing reticulocytes (F reticulocytes) or red cells (F cells). In contrast, hydroxyurea treatment was associated with a 3-to-25-fold increase in F reticulocytes, a 1.6-to-7-fold increase in F cells, and a 2.3-to-16-fold increase in the percentage of hemoglobin F. In all three patients given hydroxyurea, treatment with this drug was associated with reduced hemolysis, shown by decreases in serum bilirubin and lactic dehydrogenase and prolongation of red-cell survival. Hydroxyurea treatment also resulted in a decrease in the percentage of irreversibly sickled cells and sickling at partial oxygen saturation, an increase in oxygen affinity and total red-cell cation content, and a reduction in potassium-chloride cotransport. All three patients had a decrease in the number of pain crises. CONCLUSIONS. This study confirms that hydroxyurea therapy increases hemoglobin F production and provides objective evidence that hydroxyurea reduces the rate of hemolysis and intracellular polymerization of hemoglobin S. In contrast, recombinant human erythropoietin, whether alone or in combination with hydroxyurea, offers no measurable benefit.
Source Information
Department of Medicine, Brigham and Women's Hospital, MA 02115.
This article has been cited by other articles:
Romanelli, M., Dini, V., Romanelli, P.
(2007). Hydroxyurea-Induced Leg Ulcers Treated With a Protease-Modulating Matrix. Arch Dermatol
143: 1310-1313
[Abstract][Full Text]
Weiner, D. L., Brugnara, C.
(2003). Hydroxyurea and Sickle Cell Disease: A Chance for Every Patient. JAMA
289: 1692-1694
[Full Text]
Gabbianelli, M., Testa, U., Massa, A., Morsilli, O., Saulle, E., Sposi, N. M., Petrucci, E., Mariani, G., Peschle, C.
(2003). HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood
101: 2826-2832
[Abstract][Full Text]
Ware, R. E., Eggleston, B., Redding-Lallinger, R., Wang, W. C., Smith-Whitley, K., Daeschner, C., Gee, B., Styles, L. A., Helms, R. W., Kinney, T. R., Ohene-Frempong, K.
(2002). Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood
99: 10-14
[Abstract][Full Text]
Gabbianelli, M., Testa, U., Massa, A., Pelosi, E., Sposi, N. M., Riccioni, R., Luchetti, L., Peschle, C.
(2000). Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood
95: 3555-3561
[Abstract][Full Text]
Glover, R. E., Ivy, E. D., Orringer, E. P., Maeda, H., Mason, R. P.
(1999). Detection of Nitrosyl Hemoglobin in Venous Blood in the Treatment of Sickle Cell Anemia with Hydroxyurea. Mol. Pharmacol.
55: 1006-1010
[Abstract][Full Text]
Steinberg, M. H.
(1999). Management of Sickle Cell Disease. NEJM
340: 1021-1030
[Full Text]
Bunn, H. F.
(1999). Induction of Fetal Hemoglobin in Sickle Cell Disease. Blood
93: 1787-1789
[Full Text]
Bunn, H. F.
(1997). Pathogenesis and Treatment of Sickle Cell Disease. NEJM
337: 762-769
[Full Text]
Cazzola, M., Mercuriali, F., Brugnara, C.
(1997). Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood
89: 4248-4267
[Full Text]
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., Bonds, D. R., The Investigators of the Multicenter Study of Hydr,
(1995). Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia. NEJM
332: 1317-1322
[Abstract][Full Text]
Tabbara, I. A.
(1993). Erythropoietin: Biology and Clinical Applications. Arch Intern Med
153: 298-304
[Abstract]
Rodgers, G. P., Dover, G. J., Uyesaka, N., Noguchi, C. T., Schechter, A. N., Nienhuis, A. W.
(1993). Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease. NEJM
328: 73-80
[Abstract][Full Text]
Rodgers, G. P.
(1991). Recent Approaches to the Treatment of Sickle Cell Anemia. JAMA
265: 2097-2101
[Abstract]
(1990). A PROMISING NEW TREATMENT FOR SICKLE CELL DISEASE. JWatch General
1990: 2-2
[Full Text]
Previous
